CleanCap® FLuc mRNA - (L-7602)

CleanCap®Firefly Luciferase mRNA
SKU Unit Size Price Qty
L-7602-100 100 µg
$304.00
L-7602-1000 1 mg
$1,636.00
L-7602-5 5 x 1 mg
$5,803.00

Description

The FLuc mRNA will express a luciferase protein, originally isolated from the firefly, Photinus pyralis. FLuc is commonly used in mammalian cell culture to measure both gene expression and cell viability. It emits bioluminescence in the presence of the substrate, luciferin.

This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated and optimized for mammalian systems. It mimics a fully processed mature mRNA.

Product Details

Catalog No L-7602
Purity Passes Agarose Gel Mobility
Length 1929 nucleotides
Base Composition Unmodified bases
Concentration 1.0 mg/mL
Buffer 1 mM Sodium Citrate pH 6.4
Conversion Factor 40 µg/OD260
Recommended Storage At or below -40°C
Application Reporter Genes
Other Name(s) CleanCap®Firefly Luciferase mRNA


Product FAQs


Certificate of Analysis


Intellectual Property

CleanCap For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patent or patent pending,see trilinkbiotech.com/legal-notices.

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission of Seller. No license under any patent or other intellectual property right of Seller or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.



References

Li, Bin; Luo, Xiao; Deng, Binbin; Giancola, JoLynn B.; McComb, David W.; Schmittgen, Thomas D.; Dong, Yizhou . Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA.

Marceau, Caleb D.; Puschnik, Andreas S.; Majzoub, Karim; Ooi, Yaw Shin; Brewer, Susan M.; Fuchs, Gabriele; Swaminathan, Kavya; Mata, Miguel A.; Elias, Joshua E.; Sarnow, Peter; Carette, Jan E. . Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens.

Mahiny, Azita Josefine; Karikó, Katalin . Measuring Hematocrit in Mice Injected with In Vitro-Transcribed Erythropoietin mRNA.

Luo, X.; Li, B.; Zhang, X.; Zhao, W.; Bratasz, A.; Deng, B.; McComb, D. W.; Dong, Y. . Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents.

Li, Jiahe; Wang, Wade; He, Yanpu; Li, Yingzhong; Yan, Emily Z.; Zhang, Ketian; Irvine, Darrell J.; Hammond, Paula T. . Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery.

Verbeke, Rein; Lentacker, Ine; Wayteck, Laura; Breckpot, Karine; Van Bockstal, Mieke; Descamps, Benedicte; Vanhove, Christian; De Smedt, Stefaan C.; Dewitte, Heleen . Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA.

Prieve, Mary G.; Harvie, Pierrot; Monahan, Sean D.; Roy, Debashish; Li, Allen G.; Blevins, Teri L.; Paschal, Amber E.; Waldheim, Matt; Bell, Eric C.; Galperin, Anna; Ella-Menye, Jean-Rene; Houston, Michael E. . Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency.

Schoellhammer, Carl M.; Lauwers, Gregory Y.; Goettel, Jeremy A.; Oberli, Matthias A.; Cleveland, Cody; Park, June Y.; Minahan, Daniel; Chen, Yiyun; Anderson, Daniel G.; Jaklenec, Ana; Snapper, Scott B.; Langer, Robert; Traverso, Giovanni . Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice.

Jiang, Yuhang; Gaudin, Alice; Zhang, Junwei; Agarwal, Tushar; Song, Eric; Kauffman, Amy C.; Tietjen, Gregory T.; Wang, Yongheng; Jiang, Zhaozhong; Cheng, Christopher J.; Saltzman, W. Mark . A "top-down" approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery.

Ball, Rebecca L.; Hajj, Khalid A.; Vizelman, Jamie; Bajaj, Palak; Whitehead, Kathryn A. . Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.

Roces, CB;Lou, G;Jain, N;Abraham, S;Thomas, A;Halbert, GW;Perrie, Y; . Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics

Li, L;Long, J;Sang, Y;Wang, X;Zhou, X;Pan, Y;Cao, Y;Huang, H;Yang, Z;Yang, J;Wang, S; . Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid

Romanelli, S; . CRISPR/Cas9 Inducible Gene Knockout in Brown Adipose Tissue

Meyer, RA;Patrick Hussmann, G;Peterson, NC;Luis Santos, J;Tuesca, AD; . A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery

Kenjo, E;Hozumi, H;Makita, Y;Iwabuchi, KA;Fujimoto, N;Matsumoto, S;Kimura, M;Amano, Y;Ifuku, M;Naoe, Y;Inukai, N;Hotta, A; . Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice

Tanaka, H;Miyama, R;Sakurai, Y;Tamagawa, S;Nakai, Y;Tange, K;Yoshioka, H;Akita, H; . Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles

Ali, S;Dussouillez, C;Padilla, B;Frisch, B;Mason, AJ;Kichler, A; . Design of a new cell penetrating peptide for DNA, siRNA and mRNA delivery



""